GRI Stock Overview
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GRI Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.43 |
| 52 Week High | US$62.23 |
| 52 Week Low | US$0.41 |
| Beta | 0 |
| 1 Month Change | -42.83% |
| 3 Month Change | -79.18% |
| 1 Year Change | -99.12% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| GRI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.9% | 0.4% | 1.0% |
| 1Y | -99.1% | 0.9% | 21.9% |
Return vs Industry: GRI underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: GRI underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| GRI volatility | |
|---|---|
| GRI Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRI's share price has been volatile over the past 3 months.
Volatility Over Time: GRI's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 4 | W. Hertz | www.gribio.com |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder.
GRI Bio, Inc. Fundamentals Summary
| GRI fundamental statistics | |
|---|---|
| Market cap | US$1.38m |
| Earnings (TTM) | -US$13.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs GRI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.04m |
| Earnings | -US$13.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GRI perform over the long term?
See historical performance and comparison